A Flexible MRgHITU Platform for Precise and Incision-free Ablative Therapies
Please join Profound Medical and guest speakers, Dr. Karun Sharma, Prof. Christoph Binkert, and Dr. AeRang Kim, as they discuss the flexibility of the Sonalleve system! This webinar will give a comprehensive overview on how the Sonalleve MRgHITU platform enables clinicians to deliver customizable and incision-free pain management therapies with a focus on benign and malignant tumors in pediatric and young adults patients.
We look forward to having you join us!
Registration will close 1 hour before the webinar start time!
12 – 1 pm EST | 6 – 7 pm CET
Registration is closed.
Karun V. Sharma, MD, PhD, FSIR
Director, Interventional Radiology
Principal Investigator, Bioengineering Initiative, SZI
Children’s National Hospital
Dr. Karun V. Sharma is the Director of Interventional Radiology at Children’s National Hospital, and an Associate Professor of Pediatrics at the George Washington University School of Medicine and Health Sciences. His clinical practice and translational research focuses on minimally invasive and noninvasive therapies for pediatric musculoskeletal and oncology conditions.
Dr. Sharma leads the Image-Guided Non-Invasive Therapeutic Energy (IGNITE) program, a collaboration of the Sheikh Zayed Institute and the departments of Radiology, Oncology, Surgery, and Anesthesiology at Children’s National Hospital. The IGNITE program aims to improve the quality of life and outcomes for pediatric patients through the development and clinical translation of novel minimally invasive and noninvasive surgery technologies and combination therapy approaches, with the ultimate goal of making pediatric surgery more precise, less invasive, and pain-free.
In the recent years, Dr. Sharma has concentrated on developing novel Magnetic Resonance Imaging –guided High Intensity Focused Ultrasound (MR-HIFU) applications for the pediatric patient population and lead clinical trials for osteoid osteoma. Dr. Sharma’s latest research results indicate that MR-HIFU can be performed safely and with good clinical response in various benign and malignant tumors, but without any incisions or ionizing radiation exposure to children.
Prof. Christoph Binkert
Chairman of Radiology,
Kantonsspital Winterthur, Switzerland
Christoph Binkert received his Medical Degree at the University of Zurich Switzerland. After a residency in Diagnostic Radiology in Switzerland he subspezialzed in Interventional Radiology at the Dotter Institute in Portland, Oregon, USA (2000-2002). After his fellowship he joined the faculty at the Brigham and Women’s Hospital/ Harvard Medical school where he was promoted to Associate Professor in 2006. At the Brigham and Women’s Hospital he had his first contact with MR Focused Ultrasound in the treatment of uterine fibroids.
In 2007 he was appointed as a chairman of Radiology and Nuclear Medicine of the Kantonsspital Winterthur, Switzerland and in 2010 he become a Professor of Radiology at University of Zurich, Switzerland. Starting in 2012 he began to intensify his work with MR guided Focused Ultrasound. Initially the main focus was on uterine fibroids, then research around breast treatment and desmoid was started. More recently the treatment of musculoskeletal diseases, such as symptomatic sacro-iliac joints, became more and more popular.
The investigation and the clinical implementation of MR guided focused ultrasound as a non-invasive and sustainable therapy option is an ongoing interest of Prof. Binkert.
AeRang Kim, MD, PhD
Director of Clinical Research
Division of Oncology
Center for Cancer and Blood Disorders
Children’s National Hospital
Associate Professor of Pediatrics
The George Washington School of Medicine
Dr. AeRang Kim is the Clinical Director of Research for the Division of Oncology, Associate Professor of Pediatrics and Solid Tumors Faculty member at Children’s National Hospital specializing in sarcomas, NF1-associated tumors, and developmental therapeutics.
Dr. Kim’s research has focused on the development of novel therapies for pediatric cancer, sarcomas, and NF1-associated tumors. These therapies include magnetic resonance -guided high intensity focused ultrasound (MR-HIFU) - an innovative technique that allows for non-invasive treatment of tumors either by ablation or with hyperthermia and temperature sensitive drug carriers.
Dr. Kim currently serves as the Principal Investigator in a safety and feasibility trial using MR-HIFU for the ablation of relapsed pediatric solid tumors including desmoid tumors, and in a Phase 1 study of lyso-thermosensitive liposomal doxorubicin and MR-HIFU for treatment of relapsed or refractory solid tumors in children, adolescents, and young adults.